Haruhiko Murata

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    Vaccine 29:3155-61. 2011
  2. doi request reprint A quantitative PCR assay for SV40 neutralization adaptable for high-throughput applications
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    J Virol Methods 162:236-44. 2009
  3. doi request reprint Identification of a neutralization epitope in the VP1 capsid protein of SV40
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products CBER, FDA Bethesda, MD 20892, USA
    Virology 381:116-22. 2008
  4. pmc Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS ONE 8:e56023. 2013
  5. ncbi request reprint Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s
    Keith Peden
    Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Virology 370:63-76. 2008
  6. pmc Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 5:e14416. 2010
  7. ncbi request reprint Identification of a mutation in the SV40 capsid protein VP1 that influences plaque morphology, vacuolization, and receptor usage
    Haruhiko Murata
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 370:343-51. 2008
  8. pmc A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment
    Jan C Varada
    Laboratory of DNA Viruses, Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA
    Virol J 10:195. 2013
  9. doi request reprint Development of a Luciferase Immunoprecipitation System Assay To Detect IgG Antibodies against Human Respiratory Syncytial Virus Nucleoprotein
    Sangeeta Kumari
    Laboratory of Pediatric and Respiratory Virus Diseases, Division of Viral Products, Office of Vaccines Research and Review, CBER, FDA, Bethesda, Maryland, USA
    Clin Vaccine Immunol 21:383-90. 2014

Collaborators

  • Keith Peden
  • Judy A Beeler
  • Majid Laassri
  • Belete Teferedegne
  • Sangeeta Kumari
  • Thembi Mdluli
  • Jan C Varada
  • Andrew M Lewis
  • Roberta Lynne Crim
  • Ashwin Kulkarni
  • Susette A Audet
  • R Lynne Crim
  • Susette Audet
  • Mariam Quinones

Detail Information

Publications9

  1. doi request reprint Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    Vaccine 29:3155-61. 2011
    ....
  2. doi request reprint A quantitative PCR assay for SV40 neutralization adaptable for high-throughput applications
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    J Virol Methods 162:236-44. 2009
    ..A similar high-throughput approach might be feasible for related polyomaviruses (e.g., BKV and JCV) as well as for other families of viruses...
  3. doi request reprint Identification of a neutralization epitope in the VP1 capsid protein of SV40
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products CBER, FDA Bethesda, MD 20892, USA
    Virology 381:116-22. 2008
    ..Structural information regarding the neutralization epitope should be useful for clarifying the extent of cross-reactivity exhibited by the humoral immune response towards related primate polyomaviruses (e.g., SV40, BKV, and JCV)...
  4. pmc Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS ONE 8:e56023. 2013
    ..Finally, our qRT-PCR-based approach may be broadly applicable to the development of neutralization assays for a wide variety of viruses...
  5. ncbi request reprint Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s
    Keith Peden
    Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Virology 370:63-76. 2008
    ..These results, and those of others, suggest that a limited number of SV40 strains might exist in rhesus macaques in the United States, and thus determining the origin of the SV40 sequences detected in human tumors might be difficult...
  6. pmc Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 5:e14416. 2010
    ..These results may prove to be relevant to the biology of neoplastic development. In addition, one or more of these miRNAs could be biomarkers for the expression of a tumorigenic phenotype...
  7. ncbi request reprint Identification of a mutation in the SV40 capsid protein VP1 that influences plaque morphology, vacuolization, and receptor usage
    Haruhiko Murata
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 370:343-51. 2008
    ..This VP1 mutation was identified as a genetic determinant influencing a number of phenotypes associated with SV40-LP(KT) such as plaque morphology, intracellular vacuole formation, and ganglioside receptor usage...
  8. pmc A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment
    Jan C Varada
    Laboratory of DNA Viruses, Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA
    Virol J 10:195. 2013
    ..Its lack of use may not be surprising considering that sample nucleic acid extraction and purification can be expensive, labor-intensive, and rate-limiting...
  9. doi request reprint Development of a Luciferase Immunoprecipitation System Assay To Detect IgG Antibodies against Human Respiratory Syncytial Virus Nucleoprotein
    Sangeeta Kumari
    Laboratory of Pediatric and Respiratory Virus Diseases, Division of Viral Products, Office of Vaccines Research and Review, CBER, FDA, Bethesda, Maryland, USA
    Clin Vaccine Immunol 21:383-90. 2014
    ..The LIPS-NRSV assay detects specific anti-RSV-N IgG responses that may be used as a biomarker of RSV infection. ..